

THE UNITED STATES PATENT AND TRADEMARK OFFICE

REVOCATION AND NEW POWER OF ATTORNEY AND
CHANGE OF CORRESPONDENCE ADDRESS

I, **John S. Senaldi, President and CEO of Transform Pharmaceuticals, Inc.**, the Assignee of the entire right, title, and interest in the ***U.S. Patent Application(s) and/or Patent(s) identified on the attached Schedule A***, hereby revoke all previous powers of attorney or authorizations of agent given and do hereby appoint the attorneys or agents associated with the following Customer Number, with full power of substitution and revocation, to prosecute and transact all business in the U.S. Patent and Trademark Office connected therewith for the ***U.S. Patent Application(s) and/or Patent(s) listed in the attached Schedule A***:


Customer Number: 76656

Please direct all correspondence in connection with said ***U.S. Patent Application(s) and/or Patent(s)*** to:

Customer Number: 76656

Respectfully submitted,

Date: 09-17-2010



John S. Senaldi
President and CEO
Transform Pharmaceuticals, Inc.

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

STATEMENT UNDER 37 CFR 3.73(b)


Transform Pharmaceuticals, Inc., a Delaware Corporation, pursuant to 37 CFR 3.73(b), hereby states that it is the Assignee of the entire right, title, and interest in ***U.S. Patent Application(s) and/or Patent(s) on the attached Schedule A.***

The entire right, title, and interest in the aforementioned Patent Application(s) and/or Patent(s) were conveyed to ***Transform Pharmaceuticals, Inc.*** via Assignment(s) recorded with the United States Patent and Trademark Office at the ***Reel/Frame Numbers on the attached Schedule A.***

The undersigned, ***John S. Senaldi, President and CEO***, has full authorization to act on behalf of Assignee, ***Transform Pharmaceuticals, Inc.***

Respectfully submitted,

Date: 09-17-2010



John S. Senaldi
President and CEO
Transform Pharmaceuticals, Inc.

Schedule A						
Application Number	Filing Date	Patent Number	Issue Date	Title	Current Assignee	Reel/Frame
12/015,694	1/17/2008			NOVEL FLUNARIZINE SALT FORMS AND METHODS OF MAKING AND USING THE SAME	Transform Pharmaceuticals, Inc.	020695/0051
10/533,420	4/29/2005			METHOD FOR DETERMINING EFFECT OF PREFORMULATION FORMS ON THEIR DISSOLUTION RATES	Transform Pharmaceuticals, Inc.	015742/0041
12/143,220	6/20/2008			METHODS OF MANIPULATING SMALL AMOUNTS OF SOLIDS	Transform Pharmaceuticals, Inc.	015204/0358 &
10/599,804	10/20/2008			METHODS AND SYSTEMS FOR ANALYZING SOLIDS	Transform Pharmaceuticals, Inc.	015630/0810 021716/0848
11/413,353	4/28/2006	7,763,112	7/27/2010	METHODS AND SYSTEMS FOR CO-CRYSTAL SYNTHESIS	Transform Pharmaceuticals, Inc.	017709/0345
09/994,585	11/27/2001	7,108,970	9/19/2006	RAPID IDENTIFICATION OF CONDITIONS, COMPOUNDS, OR COMPOSITIONS THAT INHIBIT, PREVENT, INDUCE, MODIFY, OR REVERSE TRANSITIONS OF PHYSICAL STATE	Transform Pharmaceuticals, Inc.	012578/0966
10/235,922	9/6/2002	6,977,723	12/20/2005	APPARATUS AND METHOD FOR HIGH-THROUGHPUT PREPARATION AND SPECTROSCOPIC CLASSIFICATION AND CHARACTERIZATION OF COMPOSITIONS	Transform Pharmaceuticals, Inc.	013631/0700
11/051,517	1/31/2005	7,061,605	6/13/2006	APPARATUS AND METHOD FOR HIGH-THROUGHPUT PREPARATION AND SPECTROSCOPIC CLASSIFICATION AND CHARACTERIZATION OF COMPOSITIONS	Transform Pharmaceuticals, Inc.	015798/0826

Schedule A						
Application Number	Filing Date	Patent Number	Issue Date	Title	Current Assignee	Reel/Frame
09/904,725	7/13/2001	6,758,099	7/6/2004	SYSTEM AND METHOD FOR OPTIMIZING TISSUE BARRIER TRANSFER OF COMPOUNDS	Transform Pharmaceuticals, Inc.	012009/0040 &
10/282,505	10/28/2002	6,852,526	2/8/2005	TRANSDERMAL ASSAY WITH MAGNETIC CLAMP	Transform Pharmaceuticals, Inc.	014006/0615 & 013442/0214
10/371,372	2/20/2003	7,172,859	2/6/2007	SYSTEM AND METHOD FOR OPTIMIZING TISSUE BARRIER TRANSFER OF COMPOUNDS	Transform Pharmaceuticals, Inc.	015564/0762 & 012009/0040
11/467,091	8/24/2006			COMPUTERIZED CONTROL OF HIGH-THROUGHPUT TRANSDERMAL EXPERIMENTAL PROCESSING AND DIGITAL ANALYSIS OF COMPARATIVE SAMPLES	Transform Pharmaceuticals, Inc.	014006/0615 & 018361/0356
10/694,639	10/27/2003	7,449,307	11/11/2008	RAISED SURFACE ASSAY PLATE	Transform Pharmaceuticals, Inc.	014482/0118
10/555,996	12/18/2005			RAISED SURFACE ASSAY PLATE	Transform Pharmaceuticals, Inc.	018647/0734
10/439,943	5/16/2003	6,908,760	6/21/2005	RAISED SURFACE ASSAY PLATE	Transform Pharmaceuticals, Inc.	014158/0296
11/573,237	8/4/2005			NOVEL FENOFIBRATE FORMULATIONS AND RELATED METHODS OF TREATMENT	Transform Pharmaceuticals, Inc.	018025/0731
11/197,880	8/5/2005	7,542,287	1/5/2010	NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT	Transform Pharmaceuticals, Inc.	017319/0723
11/462,142	8/3/2006			NOVEL FORMULATIONS COMPRISING FENOFIBRATE AND A STATIN, AND RELATED METHODS OF TREATMENT	Transform Pharmaceuticals, Inc.	018048/0693
10/700,146	11/3/2003	7,449,342	11/11/2008	METHODS OF MANIPULATING SMALL AMOUNTS OF SOLIDS	Transform Pharmaceuticals, Inc.	015204/0358 & 015630/0810

Schedule A

Application Number	Filing Date	Patent Number	Issue Date	Title	Current Assignee	Reel/Frame
10/343,780	11/20/2001	6,919,370	7/19/2005	PHARMACEUTICAL FORMULATIONS COMPRISING PACLITAXEL, DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF	Transform Pharmaceuticals, Inc.	015622/0342
11/103,239	4/11/2005	7,521,254	4/21/2009	QUANTITATIVE MEASUREMENTS OF CONCENTRATION AND SOLUBILITY USING RAMAN SPECTROSCOPY	Transform Pharmaceuticals, Inc.	016787/0026
11/060,180	2/17/2005	7,408,632	8/5/2008	MISCIBILITY DETERMINATION OF A COMBINATION OF LIQUIDS	Transform Pharmaceuticals, Inc.	015798/0960